Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXCEED 1: Secukinumab vs Adalimumab in Psoriatic Arthritis
NCT02745080Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2017
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies
- Countries
- 26
01
Overview
A Phase 3 trial of secukinumab in psoriatic arthritis (PsA), sponsored by Novartis. Started Apr 2017; status: completed.
02
Drugs
secukinumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT02745080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02745080.